Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
BD (NYSE: BDX) has initiated a significant clinical trial for its GalaFLEX LITE™ Scaffold in breast implant revision surgery. The first patient has been treated in an IDE clinical trial aimed at obtaining FDA Premarket Approval for reducing capsular contracture recurrence.
The STANCE study will evaluate the scaffold's effectiveness in decreasing capsular contracture, a common complication affecting 10-20% of breast implant surgeries. The trial targets enrollment of at least 250 patients across 40 investigative sites, with patients randomized 2:1 to receive either GalaFLEX LITE™ Scaffold or standard care.
The scaffold, made from P4HB (a bioabsorbable polymer), is designed to provide immediate strength during healing. Five medical centers are currently enrolling patients, marking BD's advancement in biomaterial science for tissue reconstruction.
BD (NYSE: BDX), a leading global medical technology company, has announced its participation in two upcoming healthcare investor conferences. The company will present at Citi's 2025 Unplugged Medtech and Life Sciences Access Day on February 27, 2025, at 8:45 a.m. Eastern Time, and at the Barclays 27th Annual Global Healthcare Conference on March 11, 2025, at 8:30 a.m. Eastern Time.
Investors and interested parties can access live webcasts of both presentations through the BD investor relations website at investors.bd.com. Recordings of the presentations will be made available for replay on the same platform after the events conclude.
BD (NYSE: BDX) announced plans to separate its Biosciences and Diagnostic Solutions business from the core company to enhance strategic focus and value creation. The separation will create two distinct entities:
1. 'New BD': A pure-play medical technology company with projected FY2024 revenue of $17.8 billion, focusing on four segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional. It will target a $70+ billion addressable market with 90% recurring revenue.
2. Biosciences and Diagnostic Solutions: Expected to generate $3.4 billion in FY2024 revenue, targeting a $22+ billion market with 80% recurring revenue and ~30% adjusted EBITDA margins. This entity will focus on immunology, cancer research solutions, and diagnostic services.
The company plans to announce specific separation details by the end of fiscal 2025, with completion targeted for fiscal 2026. The transaction structure remains under consideration, with options including a Reverse Morris Trust, sale, or spin-off.
BD (NYSE: BDX) reported strong Q1 fiscal 2025 results, with revenue reaching $5.2 billion, representing a 9.8% increase as reported, 9.6% currency-neutral, and 3.9% organic growth. The company demonstrated robust financial performance with GAAP diluted EPS of $1.04 (up 8.3%) and adjusted diluted EPS of $3.43 (up 28.0%).
The company has completed $750 million in share repurchases to date in FY25 and has increased its FY25 adjusted diluted EPS guidance at the midpoint while absorbing translational currency impacts. BD also announced plans to separate its Biosciences and Diagnostic Solutions businesses to enhance value creation and focus on market-specific growth strategies.
BD (NYSE: BDX) has announced several key financial decisions. The Board declared a quarterly dividend of $1.04 per common share, payable on March 31, 2025, to shareholders of record on March 10, 2025, indicating an annual dividend rate of $4.16 per share.
The company has already completed $750 million in stock repurchases in fiscal 2025. Additionally, the Board authorized the repurchase of up to 10 million additional shares of BD common stock, supplementing the remaining shares available under the 2021 authorization. The company maintains flexibility in executing these repurchases through various methods, with timing and volume determined by management based on market conditions and business factors.
BD (NYSE: BDX) and Biosero announced a collaboration agreement to integrate robotic arms with BD flow cytometry instruments, aiming to accelerate drug discovery and development. The partnership will develop new software capabilities making BD flow cytometer instruments compatible with Biosero's Green Button Go® software.
The collaboration addresses the current manual processes in flow cytometry workflows, enabling automation of sample loading and analysis. Instead of manually changing multiwell plates one at a time, robotic integration will allow automatic processing of potentially hundreds of plates without human intervention.
The new software versions will be available for research use in 2025 for the BD FACSymphony A1™ Cell Analyzer, BD FACSymphony™ A5 SE Cell Analyzer, and BD FACSLyric™ Flow Cytometry System, with future integration planned for the BD FACSDiscover™ family of instruments.
BD (NYSE: BDX) and Biosero announced a collaboration to integrate robotic automation with BD flow cytometry instruments, aiming to accelerate drug discovery and development processes. The partnership will develop new software capabilities making BD flow cytometer instruments compatible with Biosero's Green Button Go® software.
The integration will automate manual processes in flow cytometry workflows, enabling automatic handling of multiple multiwell plates without human intervention. This automation advancement is particularly significant for biopharma companies and research organizations conducting high-throughput drug screening and cell therapy manufacturing.
The compatible software versions for BD FACSymphony A1, FACSymphony A5 SE, and FACSLyric Flow Cytometry System will be available for research use in 2025. Future integration is planned for the BD FACSDiscover family of instruments.
Carilion Clinic, serving over 1 million people in Virginia, has partnered with BD (NYSE: BDX) to become the first health system in Virginia and the Southeastern U.S. to implement needle-free blood draws using the BD® PIVO™ Pro Blood Collection Device.
The technology allows clinicians to draw blood through existing peripheral IV catheter lines, reducing multiple needlesticks, pain, and anxiety for patients. According to a Harris Poll, 51% of Americans report some fear of needles, with 31% specifically fearing multiple needle insertions.
The implementation begins at Carilion Roanoke Memorial Hospital with plans to expand to other Carilion facilities throughout the year. This initiative aims to improve patient care quality, reduce needlestick injuries, and streamline clinical workflows while minimizing complications that could lead to redraws and care delays.
BD (NYSE: BDX) has announced it will host an audio webcast on February 6, 2025, at 8 a.m. ET to discuss its first quarter fiscal 2025 financial results for the period ending December 31, 2024. During the webcast, management will present the quarterly results and provide updates on company operations and strategy.
The company will release financial summary materials and a news release prior to the webcast. Investors can access the webcast through BD's investor relations website, where a replay will also be available afterward.
BD (NYSE: BDX) announced major investments in its U.S. manufacturing capabilities for critical medical devices. The company invested over $10 million in 2024 to expand production capacity, adding new needle and syringe lines in Connecticut and Nebraska facilities. This expansion will increase domestic production of safety-engineered injection devices by >40% and conventional syringes by >50%, adding hundreds of millions of units annually.
The company hired 215 full-time employees to support increased production. Additionally, BD plans to invest over $30 million in 2025 to expand IV line manufacturing capacity at its Utah plant, following a $2 million investment in 2024 that increased IV catheter output by >40 million units annually.
BD operates more than 30 manufacturing and distribution facilities across 17 U.S. states and Puerto Rico, employing over 10,000 people. Key facilities include Nebraska (opened 1949), Connecticut (1961), and Utah (1956), which collectively represent 200 years of manufacturing experience.
FAQ
What is the current stock price of Becton Dickinson & Co (BDX)?
What is the market cap of Becton Dickinson & Co (BDX)?
